29 Jun 2020 Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
11 Jun 2020 Oblique Therapeutics AB has identified a potentially important epitope for generation of SARS-CoV-2 antibodies
